Sarepta Therapeutics

Showing 6 posts of 6 posts found.

FDA pre-meeting report raises concerns over Sarepta’s gene therapy for Duchenne muscular dystrophy

May 11, 2023
Medical Communications Duchenne Muscular Dystrophy, FDA, Musculo-skeletal disorder, Sarepta Therapeutics, gene therapy

The US Food and Drug Administration (FDA) has released a report in preparation for its 12 May decision on Sarepta …


Sarepta appoints ex-Allergan President as new CEO

June 29, 2017
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Sarepta Therapeutics

Sarepta Therapeutics has announced the appointment of ex-Allergan President Doug Ingram as the company’s new CEO – it’s third in …


Weekly Movers: XenoPort, Akari, Bayer…

May 31, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Bayer, Sarepta Therapeutics, Stick Market, Stock, Xenoport, finance

Bayer-Monsanto story comes close on the heels of Sanofi-Medivation tussle as the pharma sector goes through the motions of consolidation. …


Shares plunge at Sarepta after negative FDA review on muscle disorder drug

April 21, 2016
Research and Development, Sales and Marketing FDA, Sarepta Therapeutics, Shares, dive, fall, negative, plunge, sarepta

Sarepta Therapeutics (NASDAQ: SPRT) is counting the cost as shares plunge following a negative review given by staff at the …


US FDA sets April 25 date to review Sarepta’s DMD drug, shares jump

March 11, 2016
Medical Communications, Research and Development Duchenne Muscular Dystrophy, Eteplirsen, Sarepta Therapeutics, US FDA

Shares in US-based Sarepta Therapeutics (Nasdaq: SRPT) jumped nearly 15% Thursday after the US Food and Drug Administration (FDA) said it …

Latest content